Your B2B Partner for Innovation in Health, Wellbeing, Cosmetics and Life Science Over 20 years of experience in the production and use of Ectoin® and other extremolytes makes bitop a valuable and trustworthy partner for the pharmaceutical, cosmetics, and life science industries.

CJ CheilJedang is a core subsidiary in charge of the food and bioengineering business Unit of the CJ Group. It has led the development of the Korean food industry for the past 60 years, and contributed to the development of the bioengineering industry as the nation’s top food originated company. After being launched in 1953 as a food ingredient company, continuously extended its business to processed foods. In 2007, CJ CheilJedang divided out as a subsidiary company to concentrate on the food and bioengineering business.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Over the past 120 years, Kerr Corporation has secured a reputation as one of the most trusted names in premiere dental consumables. Kerr manufactures a comprehensive line of products used in virtually all types of dental restorative procedures. Their sales force works closely with a network of exclusive distributors to provide technical training and support to customers worldwide. The company’s business philosophy is simple: Only by listening closely to the customer can we develop the products and strategies that will ensure our place as a market leader. The quality that sets Kerr apart from other manufacturers is our unwavering commitment to innovation. Their breakthroughs in composites, bonding agents, impression materials, cements, and restorative accessories have helped define modern dentistry. Kerr’s rich portfolio of product lines and programs reflects their commitment to listening to, understanding, and meeting the needs of our customers.

Genecor, Inc. provides engineering services. The company is headquartered in Quebec City, Canada.

Novozymes is a world leader in bioinnovation. Novozymes works with its partners to innovate new solutions and rethink industries around the world. Novozymes' industrial enzymes, microorganisms, biopolymers, and other proteins allow its customers to achieve more efficient use of raw materials, reduce energy consumption, replace traditional chemicals with more sustainable alternatives, and offer higher-quality products. Novozymes rethinks everyday products every day.

Thermostable Enzyme Laboratory Co., Ltd. is a Japanese company located in Kobe that operates as laboratory which engages in research, production and distribution of thermo stable enzymes. The firm was founded in 2003.

AgrEvo GmbH manufacturers fertilizer products. It offers crop protection and production products including seeds, pest control products and other bio- technology products. The company is headquartered in Berlin, Germany.

KOSÉ specializes mainly in the manufacturing and marketing of cosmetics. Its strength lies in its unique and high-value exclusive cosmetics. It aims to offer original and valuable products in all of its brand categories, particularly in the high-prestige and prestige brands, which are characterized by high added value, as well as the cosmetaries* brands, which offer inexpensive and affordable products, mainly in the self-service category. It also offers through various sales channels highly original brands with a wide variety of features to precisely meet the diverse needs of customers. Its brands are divided into two major categories: the KOSÉ brand, a brand that has the company’s name on it, and the individual brands, which represent a wide variety of highly original brands. It was founded in 1946 and is located in Nihonbashi, Tokyo, Japan.

ChitogenX, Inc. is a clinical stage biotech company, which engages in the development of therapeutic soft tissue repair technologies for orthopaedic and sports medicine surgeries. Its products include Ortho-R, Ortho-M, and Ortho-C. The company was founded on February 5, 2015 and is headquartered in Kirkland, Canada.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

New England Biolabs is focused on the discovery and development of recombinant and native enzymes for genomic research. It offers restriction endonucleases for DNA digestion; PCR, polymerases, and amplification technologies for PCR applications; DNA modifying enzymes and cloning technologies; reagents for DNA and RNA sample preparation; DNA, RNA, and protein markers and ladders for electrophoresis applications; reagents for RNA research; and gene expression tools for DNA, RNA, and protein transfection of cell lines. The company also offers cellular analysis solutions; reagents, enzymes, antibodies, and DNA controls for epigenetics research; protein expression and purification technologies; competent cells for transformation and protein expression; protein tools; glycobiology products; and plasmids and DNAs for use in cloning experiments. New England Biolabs was founded in 1974 and is based in Ipswich, Massachusetts.

Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates an industrial pilot, is completing the construction of its demo plant in Germany, and is preparing its first full-scale plant through a Joint-Venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 – ALGBE).

VBL Therapeutics is an innovative and diversified, clinical stage biotechnology company committed to the discovery, development and commercialization of novel treatments for cancer and immune-inflammatory diseases. Currently available therapies are limited in their ability to adequately treat these serious and oftentimes life-threatening diseases. VBL was founded to create new treatment options that address these unmet medical needs. VBL’s clinical pipeline is based on two distinct, proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. To date, VBL has developed two programs based on these platforms – an oncology program and an anti-inflammatory program.

National Research Council of Canada, provides research & development. It services include research programs and collaboration opportunities, technical and advisory services, licensing opportunities and industrial research assistance program. The company was founded by Graham W. Burton and is headquartered in Ottawa, ON.